Treatment of refractory and super-refractory status epilepticus with brivaracetam: A cohort study from two German university hospitals
- 1 May 2017
- journal article
- Published by Elsevier in Epilepsy & Behavior
- Vol. 70, 177-181
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Costs and cost‐driving factors for acute treatment of adults with status epilepticus: A multicenter cohort study from GermanyEpilepsia, 2016
- Brivaracetam add-on for refractory focal epilepsyNeurology, 2016
- Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticusExpert Review of Clinical Pharmacology, 2016
- Brivaracetam, a selective high‐affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of actionEpilepsia, 2015
- Preliminary results of the global audit of treatment of refractory status epilepticusEpilepsy & Behavior, 2015
- Status epilepticus in adultsThe Lancet Neurology, 2015
- The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapyBrain, 2012
- Super‐refractory status epilepticus: An approach to therapy in this difficult clinical situationEpilepsia, 2011
- The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocolBrain, 2011
- A “Malignant” Variant of Status EpilepticusArchives of Neurology, 2005